pe cy7 anti p mtor mrrby Search Results


pe anti-mouse cd170 (siglecf, e50-2440)  (Becton Dickinson)
90
Becton Dickinson pe anti-mouse cd170 (siglecf, e50-2440)
Pe Anti Mouse Cd170 (Siglecf, E50 2440), supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe anti-mouse cd170 (siglecf, e50-2440)/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
pe anti-mouse cd170 (siglecf, e50-2440) - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
anti p foxo1 ser256  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc anti p foxo1 ser256
a , b Representative images (left) or the percentage (right) of CD4 + Foxp3 + ( a ) ( n = 3) or p-Smad2/3 + ( b ) ( n = 3) T cells by 6F01 stimulation in a dose-dependent manner during iT reg differentiation. Treatment of 5 ng ml −1 TGF-β1 was used as a positive control. Data are expressed as mean ± S.E.M (in a Day 2 * P = 0.0226, ** P = 0.0019 Isotype IgG vs 6F01, ** P = 0.0024 Isotype IgG vs iT reg ; Day3 * P = 0.0156, ** P = 0.0012, *** P < 0.001) (in b * P = 0.0123, ** P = 0.0081). c Representative dot plots (upper) or quantification of the level of CD4 + Foxp3 + T cells in SIS3 treatment with 6F01 or isotype IgG during iT reg differentiation in a dose-dependent manner ( n = 3). Data are expressed as mean ± S.E.M (*** P < 0.001). d The level of Foxp3 mRNA from mouse iT reg cells stimulated with 6F01 or isotype control normalized with GAPDH ( left ) ( n = 3) or Hprt ( right ) ( n = 4) level. Data are expressed as mean ± S.E.M (in left panel ** P = 0.0029 No vs 6F01, ** P = 0.0044 Isotype IgG vs 6F01; in right panel * P = 0.0141, ** P = 0.0062). e The level of EGFR expression of Th0 or iT reg cells in response to isotype IgG or various 6F01 treatment using western blot analysis. β-actin was used as a quality control. The experiment was repeated three times independently with similar results. f – h Quantification of MFI of phosphorylated AKT (Ser473), mTOR (Ser2448), or <t>FoxO1</t> <t>(Ser256)</t> by stimulation of 6F01 or isotype control ( n = 3 for each group). Data are expressed as mean ± S.E.M (p-AKT: * P = 0.0164 No vs 6F01, * P = 0.0112 Isotype IgG vs 6F01; p-mTOR: ** P = 0.005 No vs 6F01, ** P = 0.001 Isotype IgG vs 6F01, *** P < 0.001; p-FoxO1: *** P < 0.001). One-way ANOVA with Dunnett’s multiple comparisons test ( a , b ) or one-way ANOVA with Tukey’s multiple comparisons test ( d , f – h ) or two-way ANOVA with Šídák’s multiple comparisons test ( c ). Source data are provided as a Source Data file.
Anti P Foxo1 Ser256, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti p foxo1 ser256/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
anti p foxo1 ser256 - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier
anti-smad2 (ps465/ps467)/smad3 (ps423/ps425  (Becton Dickinson)
90
Becton Dickinson anti-smad2 (ps465/ps467)/smad3 (ps423/ps425
a , b Representative images (left) or the percentage (right) of CD4 + Foxp3 + ( a ) ( n = 3) or <t>p-Smad2/3</t> + ( b ) ( n = 3) T cells by 6F01 stimulation in a dose-dependent manner during iT reg differentiation. Treatment of 5 ng ml −1 TGF-β1 was used as a positive control. Data are expressed as mean ± S.E.M (in a Day 2 * P = 0.0226, ** P = 0.0019 Isotype IgG vs 6F01, ** P = 0.0024 Isotype IgG vs iT reg ; Day3 * P = 0.0156, ** P = 0.0012, *** P < 0.001) (in b * P = 0.0123, ** P = 0.0081). c Representative dot plots (upper) or quantification of the level of CD4 + Foxp3 + T cells in SIS3 treatment with 6F01 or isotype IgG during iT reg differentiation in a dose-dependent manner ( n = 3). Data are expressed as mean ± S.E.M (*** P < 0.001). d The level of Foxp3 mRNA from mouse iT reg cells stimulated with 6F01 or isotype control normalized with GAPDH ( left ) ( n = 3) or Hprt ( right ) ( n = 4) level. Data are expressed as mean ± S.E.M (in left panel ** P = 0.0029 No vs 6F01, ** P = 0.0044 Isotype IgG vs 6F01; in right panel * P = 0.0141, ** P = 0.0062). e The level of EGFR expression of Th0 or iT reg cells in response to isotype IgG or various 6F01 treatment using western blot analysis. β-actin was used as a quality control. The experiment was repeated three times independently with similar results. f – h Quantification of MFI of phosphorylated AKT (Ser473), mTOR (Ser2448), or FoxO1 (Ser256) by stimulation of 6F01 or isotype control ( n = 3 for each group). Data are expressed as mean ± S.E.M (p-AKT: * P = 0.0164 No vs 6F01, * P = 0.0112 Isotype IgG vs 6F01; p-mTOR: ** P = 0.005 No vs 6F01, ** P = 0.001 Isotype IgG vs 6F01, *** P < 0.001; p-FoxO1: *** P < 0.001). One-way ANOVA with Dunnett’s multiple comparisons test ( a , b ) or one-way ANOVA with Tukey’s multiple comparisons test ( d , f – h ) or two-way ANOVA with Šídák’s multiple comparisons test ( c ). Source data are provided as a Source Data file.
Anti Smad2 (Ps465/Ps467)/Smad3 (Ps423/Ps425, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-smad2 (ps465/ps467)/smad3 (ps423/ps425/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
anti-smad2 (ps465/ps467)/smad3 (ps423/ps425 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
anti-cd45.1  (Becton Dickinson)
90
Becton Dickinson anti-cd45.1
a , b Representative images (left) or the percentage (right) of CD4 + Foxp3 + ( a ) ( n = 3) or <t>p-Smad2/3</t> + ( b ) ( n = 3) T cells by 6F01 stimulation in a dose-dependent manner during iT reg differentiation. Treatment of 5 ng ml −1 TGF-β1 was used as a positive control. Data are expressed as mean ± S.E.M (in a Day 2 * P = 0.0226, ** P = 0.0019 Isotype IgG vs 6F01, ** P = 0.0024 Isotype IgG vs iT reg ; Day3 * P = 0.0156, ** P = 0.0012, *** P < 0.001) (in b * P = 0.0123, ** P = 0.0081). c Representative dot plots (upper) or quantification of the level of CD4 + Foxp3 + T cells in SIS3 treatment with 6F01 or isotype IgG during iT reg differentiation in a dose-dependent manner ( n = 3). Data are expressed as mean ± S.E.M (*** P < 0.001). d The level of Foxp3 mRNA from mouse iT reg cells stimulated with 6F01 or isotype control normalized with GAPDH ( left ) ( n = 3) or Hprt ( right ) ( n = 4) level. Data are expressed as mean ± S.E.M (in left panel ** P = 0.0029 No vs 6F01, ** P = 0.0044 Isotype IgG vs 6F01; in right panel * P = 0.0141, ** P = 0.0062). e The level of EGFR expression of Th0 or iT reg cells in response to isotype IgG or various 6F01 treatment using western blot analysis. β-actin was used as a quality control. The experiment was repeated three times independently with similar results. f – h Quantification of MFI of phosphorylated AKT (Ser473), mTOR (Ser2448), or FoxO1 (Ser256) by stimulation of 6F01 or isotype control ( n = 3 for each group). Data are expressed as mean ± S.E.M (p-AKT: * P = 0.0164 No vs 6F01, * P = 0.0112 Isotype IgG vs 6F01; p-mTOR: ** P = 0.005 No vs 6F01, ** P = 0.001 Isotype IgG vs 6F01, *** P < 0.001; p-FoxO1: *** P < 0.001). One-way ANOVA with Dunnett’s multiple comparisons test ( a , b ) or one-way ANOVA with Tukey’s multiple comparisons test ( d , f – h ) or two-way ANOVA with Šídák’s multiple comparisons test ( c ). Source data are provided as a Source Data file.
Anti Cd45.1, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-cd45.1/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
anti-cd45.1 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier
anti mtor  (Cell Signaling Technology Inc)
97
Cell Signaling Technology Inc anti mtor
a , b Representative images (left) or the percentage (right) of CD4 + Foxp3 + ( a ) ( n = 3) or <t>p-Smad2/3</t> + ( b ) ( n = 3) T cells by 6F01 stimulation in a dose-dependent manner during iT reg differentiation. Treatment of 5 ng ml −1 TGF-β1 was used as a positive control. Data are expressed as mean ± S.E.M (in a Day 2 * P = 0.0226, ** P = 0.0019 Isotype IgG vs 6F01, ** P = 0.0024 Isotype IgG vs iT reg ; Day3 * P = 0.0156, ** P = 0.0012, *** P < 0.001) (in b * P = 0.0123, ** P = 0.0081). c Representative dot plots (upper) or quantification of the level of CD4 + Foxp3 + T cells in SIS3 treatment with 6F01 or isotype IgG during iT reg differentiation in a dose-dependent manner ( n = 3). Data are expressed as mean ± S.E.M (*** P < 0.001). d The level of Foxp3 mRNA from mouse iT reg cells stimulated with 6F01 or isotype control normalized with GAPDH ( left ) ( n = 3) or Hprt ( right ) ( n = 4) level. Data are expressed as mean ± S.E.M (in left panel ** P = 0.0029 No vs 6F01, ** P = 0.0044 Isotype IgG vs 6F01; in right panel * P = 0.0141, ** P = 0.0062). e The level of EGFR expression of Th0 or iT reg cells in response to isotype IgG or various 6F01 treatment using western blot analysis. β-actin was used as a quality control. The experiment was repeated three times independently with similar results. f – h Quantification of MFI of phosphorylated AKT (Ser473), mTOR (Ser2448), or FoxO1 (Ser256) by stimulation of 6F01 or isotype control ( n = 3 for each group). Data are expressed as mean ± S.E.M (p-AKT: * P = 0.0164 No vs 6F01, * P = 0.0112 Isotype IgG vs 6F01; p-mTOR: ** P = 0.005 No vs 6F01, ** P = 0.001 Isotype IgG vs 6F01, *** P < 0.001; p-FoxO1: *** P < 0.001). One-way ANOVA with Dunnett’s multiple comparisons test ( a , b ) or one-way ANOVA with Tukey’s multiple comparisons test ( d , f – h ) or two-way ANOVA with Šídák’s multiple comparisons test ( c ). Source data are provided as a Source Data file.
Anti Mtor, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mtor/product/Cell Signaling Technology Inc
Average 97 stars, based on 1 article reviews
anti mtor - by Bioz Stars, 2026-06
97/100 stars
  Buy from Supplier
anti akt  (Cell Signaling Technology Inc)
99
Cell Signaling Technology Inc anti akt
a , b Representative images (left) or the percentage (right) of CD4 + Foxp3 + ( a ) ( n = 3) or <t>p-Smad2/3</t> + ( b ) ( n = 3) T cells by 6F01 stimulation in a dose-dependent manner during iT reg differentiation. Treatment of 5 ng ml −1 TGF-β1 was used as a positive control. Data are expressed as mean ± S.E.M (in a Day 2 * P = 0.0226, ** P = 0.0019 Isotype IgG vs 6F01, ** P = 0.0024 Isotype IgG vs iT reg ; Day3 * P = 0.0156, ** P = 0.0012, *** P < 0.001) (in b * P = 0.0123, ** P = 0.0081). c Representative dot plots (upper) or quantification of the level of CD4 + Foxp3 + T cells in SIS3 treatment with 6F01 or isotype IgG during iT reg differentiation in a dose-dependent manner ( n = 3). Data are expressed as mean ± S.E.M (*** P < 0.001). d The level of Foxp3 mRNA from mouse iT reg cells stimulated with 6F01 or isotype control normalized with GAPDH ( left ) ( n = 3) or Hprt ( right ) ( n = 4) level. Data are expressed as mean ± S.E.M (in left panel ** P = 0.0029 No vs 6F01, ** P = 0.0044 Isotype IgG vs 6F01; in right panel * P = 0.0141, ** P = 0.0062). e The level of EGFR expression of Th0 or iT reg cells in response to isotype IgG or various 6F01 treatment using western blot analysis. β-actin was used as a quality control. The experiment was repeated three times independently with similar results. f – h Quantification of MFI of phosphorylated AKT (Ser473), mTOR (Ser2448), or FoxO1 (Ser256) by stimulation of 6F01 or isotype control ( n = 3 for each group). Data are expressed as mean ± S.E.M (p-AKT: * P = 0.0164 No vs 6F01, * P = 0.0112 Isotype IgG vs 6F01; p-mTOR: ** P = 0.005 No vs 6F01, ** P = 0.001 Isotype IgG vs 6F01, *** P < 0.001; p-FoxO1: *** P < 0.001). One-way ANOVA with Dunnett’s multiple comparisons test ( a , b ) or one-way ANOVA with Tukey’s multiple comparisons test ( d , f – h ) or two-way ANOVA with Šídák’s multiple comparisons test ( c ). Source data are provided as a Source Data file.
Anti Akt, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti akt/product/Cell Signaling Technology Inc
Average 99 stars, based on 1 article reviews
anti akt - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier

Image Search Results


a , b Representative images (left) or the percentage (right) of CD4 + Foxp3 + ( a ) ( n = 3) or p-Smad2/3 + ( b ) ( n = 3) T cells by 6F01 stimulation in a dose-dependent manner during iT reg differentiation. Treatment of 5 ng ml −1 TGF-β1 was used as a positive control. Data are expressed as mean ± S.E.M (in a Day 2 * P = 0.0226, ** P = 0.0019 Isotype IgG vs 6F01, ** P = 0.0024 Isotype IgG vs iT reg ; Day3 * P = 0.0156, ** P = 0.0012, *** P < 0.001) (in b * P = 0.0123, ** P = 0.0081). c Representative dot plots (upper) or quantification of the level of CD4 + Foxp3 + T cells in SIS3 treatment with 6F01 or isotype IgG during iT reg differentiation in a dose-dependent manner ( n = 3). Data are expressed as mean ± S.E.M (*** P < 0.001). d The level of Foxp3 mRNA from mouse iT reg cells stimulated with 6F01 or isotype control normalized with GAPDH ( left ) ( n = 3) or Hprt ( right ) ( n = 4) level. Data are expressed as mean ± S.E.M (in left panel ** P = 0.0029 No vs 6F01, ** P = 0.0044 Isotype IgG vs 6F01; in right panel * P = 0.0141, ** P = 0.0062). e The level of EGFR expression of Th0 or iT reg cells in response to isotype IgG or various 6F01 treatment using western blot analysis. β-actin was used as a quality control. The experiment was repeated three times independently with similar results. f – h Quantification of MFI of phosphorylated AKT (Ser473), mTOR (Ser2448), or FoxO1 (Ser256) by stimulation of 6F01 or isotype control ( n = 3 for each group). Data are expressed as mean ± S.E.M (p-AKT: * P = 0.0164 No vs 6F01, * P = 0.0112 Isotype IgG vs 6F01; p-mTOR: ** P = 0.005 No vs 6F01, ** P = 0.001 Isotype IgG vs 6F01, *** P < 0.001; p-FoxO1: *** P < 0.001). One-way ANOVA with Dunnett’s multiple comparisons test ( a , b ) or one-way ANOVA with Tukey’s multiple comparisons test ( d , f – h ) or two-way ANOVA with Šídák’s multiple comparisons test ( c ). Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Lrig1-expression confers suppressive function to CD4 + cells and is essential for averting autoimmunity via the Smad2/3/Foxp3 axis

doi: 10.1038/s41467-023-40986-4

Figure Lengend Snippet: a , b Representative images (left) or the percentage (right) of CD4 + Foxp3 + ( a ) ( n = 3) or p-Smad2/3 + ( b ) ( n = 3) T cells by 6F01 stimulation in a dose-dependent manner during iT reg differentiation. Treatment of 5 ng ml −1 TGF-β1 was used as a positive control. Data are expressed as mean ± S.E.M (in a Day 2 * P = 0.0226, ** P = 0.0019 Isotype IgG vs 6F01, ** P = 0.0024 Isotype IgG vs iT reg ; Day3 * P = 0.0156, ** P = 0.0012, *** P < 0.001) (in b * P = 0.0123, ** P = 0.0081). c Representative dot plots (upper) or quantification of the level of CD4 + Foxp3 + T cells in SIS3 treatment with 6F01 or isotype IgG during iT reg differentiation in a dose-dependent manner ( n = 3). Data are expressed as mean ± S.E.M (*** P < 0.001). d The level of Foxp3 mRNA from mouse iT reg cells stimulated with 6F01 or isotype control normalized with GAPDH ( left ) ( n = 3) or Hprt ( right ) ( n = 4) level. Data are expressed as mean ± S.E.M (in left panel ** P = 0.0029 No vs 6F01, ** P = 0.0044 Isotype IgG vs 6F01; in right panel * P = 0.0141, ** P = 0.0062). e The level of EGFR expression of Th0 or iT reg cells in response to isotype IgG or various 6F01 treatment using western blot analysis. β-actin was used as a quality control. The experiment was repeated three times independently with similar results. f – h Quantification of MFI of phosphorylated AKT (Ser473), mTOR (Ser2448), or FoxO1 (Ser256) by stimulation of 6F01 or isotype control ( n = 3 for each group). Data are expressed as mean ± S.E.M (p-AKT: * P = 0.0164 No vs 6F01, * P = 0.0112 Isotype IgG vs 6F01; p-mTOR: ** P = 0.005 No vs 6F01, ** P = 0.001 Isotype IgG vs 6F01, *** P < 0.001; p-FoxO1: *** P < 0.001). One-way ANOVA with Dunnett’s multiple comparisons test ( a , b ) or one-way ANOVA with Tukey’s multiple comparisons test ( d , f – h ) or two-way ANOVA with Šídák’s multiple comparisons test ( c ). Source data are provided as a Source Data file.

Article Snippet: : anti-CD3 (17A2; BioLegend) APC-cy7; anti-CD4 (RM 4-5; Thermo Fisher Scientific) FITC, APC; anti-CD4 (RM4-4; BioLegend) BV421; anti-CD8a (53-6.7; Thermo Fisher Scientific) FITC; anti-CD19 (eBio1D3(1D3), Thermo Fisher Scientific) FITC; anti-Foxp3 (FJK-16s; Thermo Fisher Scientific) FITC, PE, APC; anti-IFNγ (XMG1.2; Thermo Fisher Scientific) FITC, PE, APC; anti-IL-4 (11B11; Thermo Fisher Scientific) PE; anti-IL-17A (eBio17B7; Thermo Fisher Scientific) PE; anti-IL-10 (JES5-16E3; Thermo Fisher Scientific) PE, APC (1:200); anti-CD25 (PC61.5; Thermo Fisher Scientific) FITC, PE; anti-PD-1 (J43; Thermo Fisher Scientific) PE; anti-GITR (DTA-1; Thermo Fisher Scientific) PE; anti-TIGIT (GIGD7; Thermo Fisher Scientific) PE; anti-CTLA-4 (UC10-4B9; Thermo Fisher Scientific) PE; anti-CD62L (MEL-14; Thermo Fisher Scientific) FITC; anti-CD44 (IM7; Thermo Fisher Scientific) PE, PE-cy7; anti-CD45.1 (A20; BD Biosciences) APC-cy7; anti-CD45.2 (104; Thermo Fisher Scientific) FITC; anti-Lrig1 (polyclonal; R&D systems) AF488, PE (1:100); anti-LRIG1 (789211; R&D systems) AF488, PE (1:100); anti-Smad2 (pS465/pS467)/Smad3 (pS423/pS425) (072-670; BD Biosciences) PE (1:100); anti-AKT (C67E7; Cell Signaling Technology); anti-p-AKT1 (Ser473) (SDRNR; Thermo Fisher Scientific) APC; anti-mTOR (7C10; Cell Signaling Technology) (1:400); anti-p-mTOR (Ser2448) (MRRBY; Thermo Fisher Scientific) PE-cy7; anti-FoxO1 (C29H4; Cell Signaling Technology) (1:200); anti-p-FoxO1 (Ser256) (E1F7T; Cell Signaling Technology).

Techniques: Positive Control, Control, Expressing, Western Blot

a , b Representative images (left) or the percentage (right) of CD4 + Foxp3 + ( a ) ( n = 3) or p-Smad2/3 + ( b ) ( n = 3) T cells by 6F01 stimulation in a dose-dependent manner during iT reg differentiation. Treatment of 5 ng ml −1 TGF-β1 was used as a positive control. Data are expressed as mean ± S.E.M (in a Day 2 * P = 0.0226, ** P = 0.0019 Isotype IgG vs 6F01, ** P = 0.0024 Isotype IgG vs iT reg ; Day3 * P = 0.0156, ** P = 0.0012, *** P < 0.001) (in b * P = 0.0123, ** P = 0.0081). c Representative dot plots (upper) or quantification of the level of CD4 + Foxp3 + T cells in SIS3 treatment with 6F01 or isotype IgG during iT reg differentiation in a dose-dependent manner ( n = 3). Data are expressed as mean ± S.E.M (*** P < 0.001). d The level of Foxp3 mRNA from mouse iT reg cells stimulated with 6F01 or isotype control normalized with GAPDH ( left ) ( n = 3) or Hprt ( right ) ( n = 4) level. Data are expressed as mean ± S.E.M (in left panel ** P = 0.0029 No vs 6F01, ** P = 0.0044 Isotype IgG vs 6F01; in right panel * P = 0.0141, ** P = 0.0062). e The level of EGFR expression of Th0 or iT reg cells in response to isotype IgG or various 6F01 treatment using western blot analysis. β-actin was used as a quality control. The experiment was repeated three times independently with similar results. f – h Quantification of MFI of phosphorylated AKT (Ser473), mTOR (Ser2448), or FoxO1 (Ser256) by stimulation of 6F01 or isotype control ( n = 3 for each group). Data are expressed as mean ± S.E.M (p-AKT: * P = 0.0164 No vs 6F01, * P = 0.0112 Isotype IgG vs 6F01; p-mTOR: ** P = 0.005 No vs 6F01, ** P = 0.001 Isotype IgG vs 6F01, *** P < 0.001; p-FoxO1: *** P < 0.001). One-way ANOVA with Dunnett’s multiple comparisons test ( a , b ) or one-way ANOVA with Tukey’s multiple comparisons test ( d , f – h ) or two-way ANOVA with Šídák’s multiple comparisons test ( c ). Source data are provided as a Source Data file.

Journal: Nature Communications

Article Title: Lrig1-expression confers suppressive function to CD4 + cells and is essential for averting autoimmunity via the Smad2/3/Foxp3 axis

doi: 10.1038/s41467-023-40986-4

Figure Lengend Snippet: a , b Representative images (left) or the percentage (right) of CD4 + Foxp3 + ( a ) ( n = 3) or p-Smad2/3 + ( b ) ( n = 3) T cells by 6F01 stimulation in a dose-dependent manner during iT reg differentiation. Treatment of 5 ng ml −1 TGF-β1 was used as a positive control. Data are expressed as mean ± S.E.M (in a Day 2 * P = 0.0226, ** P = 0.0019 Isotype IgG vs 6F01, ** P = 0.0024 Isotype IgG vs iT reg ; Day3 * P = 0.0156, ** P = 0.0012, *** P < 0.001) (in b * P = 0.0123, ** P = 0.0081). c Representative dot plots (upper) or quantification of the level of CD4 + Foxp3 + T cells in SIS3 treatment with 6F01 or isotype IgG during iT reg differentiation in a dose-dependent manner ( n = 3). Data are expressed as mean ± S.E.M (*** P < 0.001). d The level of Foxp3 mRNA from mouse iT reg cells stimulated with 6F01 or isotype control normalized with GAPDH ( left ) ( n = 3) or Hprt ( right ) ( n = 4) level. Data are expressed as mean ± S.E.M (in left panel ** P = 0.0029 No vs 6F01, ** P = 0.0044 Isotype IgG vs 6F01; in right panel * P = 0.0141, ** P = 0.0062). e The level of EGFR expression of Th0 or iT reg cells in response to isotype IgG or various 6F01 treatment using western blot analysis. β-actin was used as a quality control. The experiment was repeated three times independently with similar results. f – h Quantification of MFI of phosphorylated AKT (Ser473), mTOR (Ser2448), or FoxO1 (Ser256) by stimulation of 6F01 or isotype control ( n = 3 for each group). Data are expressed as mean ± S.E.M (p-AKT: * P = 0.0164 No vs 6F01, * P = 0.0112 Isotype IgG vs 6F01; p-mTOR: ** P = 0.005 No vs 6F01, ** P = 0.001 Isotype IgG vs 6F01, *** P < 0.001; p-FoxO1: *** P < 0.001). One-way ANOVA with Dunnett’s multiple comparisons test ( a , b ) or one-way ANOVA with Tukey’s multiple comparisons test ( d , f – h ) or two-way ANOVA with Šídák’s multiple comparisons test ( c ). Source data are provided as a Source Data file.

Article Snippet: : anti-CD3 (17A2; BioLegend) APC-cy7; anti-CD4 (RM 4-5; Thermo Fisher Scientific) FITC, APC; anti-CD4 (RM4-4; BioLegend) BV421; anti-CD8a (53-6.7; Thermo Fisher Scientific) FITC; anti-CD19 (eBio1D3(1D3), Thermo Fisher Scientific) FITC; anti-Foxp3 (FJK-16s; Thermo Fisher Scientific) FITC, PE, APC; anti-IFNγ (XMG1.2; Thermo Fisher Scientific) FITC, PE, APC; anti-IL-4 (11B11; Thermo Fisher Scientific) PE; anti-IL-17A (eBio17B7; Thermo Fisher Scientific) PE; anti-IL-10 (JES5-16E3; Thermo Fisher Scientific) PE, APC (1:200); anti-CD25 (PC61.5; Thermo Fisher Scientific) FITC, PE; anti-PD-1 (J43; Thermo Fisher Scientific) PE; anti-GITR (DTA-1; Thermo Fisher Scientific) PE; anti-TIGIT (GIGD7; Thermo Fisher Scientific) PE; anti-CTLA-4 (UC10-4B9; Thermo Fisher Scientific) PE; anti-CD62L (MEL-14; Thermo Fisher Scientific) FITC; anti-CD44 (IM7; Thermo Fisher Scientific) PE, PE-cy7; anti-CD45.1 (A20; BD Biosciences) APC-cy7; anti-CD45.2 (104; Thermo Fisher Scientific) FITC; anti-Lrig1 (polyclonal; R&D systems) AF488, PE (1:100); anti-LRIG1 (789211; R&D systems) AF488, PE (1:100); anti-Smad2 (pS465/pS467)/Smad3 (pS423/pS425) (072-670; BD Biosciences) PE (1:100); anti-AKT (C67E7; Cell Signaling Technology); anti-p-AKT1 (Ser473) (SDRNR; Thermo Fisher Scientific) APC; anti-mTOR (7C10; Cell Signaling Technology) (1:400); anti-p-mTOR (Ser2448) (MRRBY; Thermo Fisher Scientific) PE-cy7; anti-FoxO1 (C29H4; Cell Signaling Technology) (1:200); anti-p-FoxO1 (Ser256) (E1F7T; Cell Signaling Technology).

Techniques: Positive Control, Expressing, Western Blot